FDA Approves Dupilumab for Chronic Spontaneous Urticaria

The Food and Drug Administration (FDA) has approved dupilumab, sold under the brand name Dupixent, as a treatment for chronic spontaneous urticaria (CSU) in patients aged 12 and older who continue to experience symptoms despite taking H1 antihistamines. This decision follows strong data from the phase 3 LIBERTY-CUPID trial, which showed that dupilumab significantly reduced the frequency and intensity of hives and itching. Chronic spontaneous urticaria is a condition marked by recurrent outbreaks of hives with no clear trigger and can severely impact sleep, productivity, and quality of life. Dupilumab works by targeting and blocking specific inflammatory pathways, namely interleukin 4 and interleukin 13, which are believed to play a central role in type 2 inflammation. The drug has already been approved to treat a range of other inflammatory conditions, including asthma, atopic dermatitis, and nasal polyps. Clinical trials have shown rapid and durable symptom relief for patients with CSU, many of whom had exhausted other treatment options. Common side effects observed during the trials included injection site reactions and conjunctivitis. For patients and clinicians, this new approval represents a much-needed option in an area with limited alternatives. It also builds on dupilumab’s expanding reputation as a versatile therapy across multiple allergic and inflammatory disorders. The approval signals the FDA’s continued prioritization of treatments for under-addressed chronic conditions. It may also encourage further research into similar biologics for dermatologic and allergic diseases. Overall, the decision brings new hope to patients who have struggled for years with the burdens of CSU.